Acadia guidance creates attractive entry point, says H.C. Wainwright

H.C. Wainwright analyst Andrew Fein believes Acadia Pharmaceuticals’ lowered guidance for 2018 creates an attractive entry point for the shares. The outlook clears the overhang on the company, which should allow for a more “pure” entry point for new investors seeking to capitalize on Acadia’s “depressed share price,” Fein tells investors in a research note. He reiterates a Buy rating on Acadia with a $60 price target.

https://bit.ly/2vSNBEd